Skip to content

Serotonin research: what the evidence shows

The neurotransmitter system central to the action of classic psychedelics and many antidepressants.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.

The research portrays serotonin as a central neuromodulator whose receptors (especially 5-HT2A) mediate psychedelic drug effects, and whose neurons are vulnerable to MDMA-type toxicity. Across studies, 5-HT2A activation is consistently linked to psilocybin's acute psychedelic and psychosis-like effects, while other serotonin receptors (5-HT1B) and intracellular 5-HT2A signaling appear to drive longer-term plasticity and anxiolytic effects. The main caveats are that much of the mechanistic evidence comes from animal, in vitro, and structural studies, human samples are small, and clinical efficacy data remain preliminary.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action 1998 experimental study Supports Psilocybin's psychotomimetic effects were blocked by the 5-HT2A antagonist ketanserin and risperidone but increased by haloperidol, supporting serotonin-2A activation as the mechanism.
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin 2000 experimental study Opposes Stimulant potency for releasing norepinephrine, not dopamine or serotonin, correlated with oral doses producing amphetamine-type subjective effects.
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction 2014 open-label pilot study 15 Supports 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up after psilocybin-assisted smoking cessation treatment.
Structural Features for Functional Selectivity at Serotonin Receptors 2013 structural biology study Supports Crystal structures of two serotonin receptor subtypes show that subtle ligand-binding differences cause substantial differences in receptor signaling and biological responses.
Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings 1998 quantitative PET study Opposes PET imaging showed a decrease in a structural component of brain serotonin neurons in human MDMA users.
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. 1984 observational study Supports 5-HT2 binding affinities of psychoactive agents correlated strongly with hallucinogenic potency in humans (r = 0.924) and with animal behavioral effects.
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo 2021 observational cohort Supports A single psilocybin dose produced ~10% increases in dendritic spine size and density in mouse medial frontal cortex within 24 hours, persisting at least one month.
Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity 1988 experimental study Opposes MDA and MDMA caused selective degeneration of serotonin axon terminals in rat forebrain while sparing catecholamine axons.
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. 1992 laboratory study Supports MDMA stimulates serotonin efflux by interacting directly with plasma membrane and vesicular serotonin transporters and by dissipating the vesicular pH gradient.
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. 1987 experimental study Opposes MDMA caused a reversible acute depletion of cortical serotonin followed by a longer-term neurotoxic depletion specific to the (+)-stereoisomer, which fluoxetine blocked.
Structural Basis for Molecular Recognition at Serotonin Receptors 2013 structural biology study Supports Crystal structures of two serotonin receptors reveal that ligand-binding differences alter receptor signaling, and the same ligand can activate one or both main signaling mechanisms depending on the receptor.
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels 2019 observational cohort 8 Supports Psilocybin produced dose-related 5-HT2A receptor occupancy up to 72%, and both occupancy and plasma psilocin levels correlated with subjective psychedelic intensity.
5-HT2AReceptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex 1997 experimental study Mixed A hallucinogenic 5-HT2A/2C agonist decreased BDNF mRNA in hippocampal dentate gyrus but increased it in neocortex, effects blocked by a 5-HT2A antagonist.
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors 2023 experimental study Supports Intracellular 5-HT2A receptors, rather than cell-surface ones, mediate psychedelic-induced cortical plasticity, which the authors say explains why serotonin does not engage similar plasticity.
Crystal structure of an LSD-bound human serotonin receptor 2017 experimental structural biology study Supports The LSD-bound 5-HT2B crystal structure and simulations suggest a lid formed by extracellular loop 2 explains LSD's slow binding kinetics at serotonin receptors.
Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice. 2026 experimental study Supports Loss of 5-HT1B receptors on forebrain excitatory neurons did not alter psilocybin's acute effects but strongly attenuated its post-acute anxiolytic effects.
Psilocybin enhances conditioned place preference learning in planarians. 2026 experimental study Supports A single psilocybin exposure enhanced appetitive associative learning in planarians, with effects persisting at least 6 days.
Serotonin biology as a basis for explaining psychedelic drug action. 2026 review Supports Argues that several major effects of psychedelics can be understood as perturbations to serotonergic signaling in reward learning, visual processing, and cerebrovascular function, while some drug actions remain hard to explain.
Ayahuasca treatment reduces 50-kHz ultrasonic vocalizations and modifies mesocorticolimbic monoamine neurochemistry in rats. 2026 randomized controlled trial Mixed Ayahuasca reduced 50-kHz ultrasonic vocalizations and spontaneous locomotion and altered mesocorticolimbic monoamine levels, including decreased medial prefrontal serotonin.
Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics. 2026 computational proof-of-concept study 4496 Supports A semantic embedding model linked 5-HT2A to classic psychedelic experience and suggested novel associations of other serotonin receptor subtypes with specific experiential categories.
Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics. 2026 systematic review and meta-analysis Mixed Serotonergic psychedelics reduced proinflammatory cytokines in inflamed murine models (SMD = -1.23) but not healthy murines, and human evidence was mixed and too limited for conclusions.
Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure 2026 theoretical paper Unclear Argues that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research, noting a randomized trial of 2 mg weekly did not beat placebo and that continuous exposure remains inadequately tested.
Deciphering the allosteric landscape of 5-HT2 receptors: integrated molecular dynamics and fragment molecular orbital analyses of activation mechanisms 2026 computational modeling study Supports Argues that 5-HT2 receptor signaling operates through a cooperative allosteric network rather than a single toggle switch, with R3.50 as a mandatory endpoint and subtype-specific differences in network organization.
Exploring a Druggable Hydrophobic Tunnel in the 5-HT2A Receptor with Potent Phenethylamines 2026 molecular pharmacology study Supports Reports that a hydrophobic tunnel lateral to the 5-HT2A orthosteric site accommodates C-4 phenyl-ring substituents of phenethylamines and contributes to agonist potency.
The serotonin 1B receptor as a target for the treatment of depression and anxiety 2026 review Supports Argues that the serotonin 1B receptor is a tractable therapeutic target for depression and anxiety, citing preclinical evidence that 5-HT1B signaling is required for psilocybin's sustained pro-hedonic and anxiolytic effects.

Points of agreement

  • 5-HT2A receptor activation is consistently linked to psilocybin's acute psychedelic and psychosis-like effects.
  • Serotonin receptors are structurally and pharmacologically diverse, with ligand-binding differences producing distinct signaling outcomes.
  • Psilocybin and related serotonergic drugs can produce lasting neural and behavioral changes beyond acute effects.
  • MDMA-type drugs act on serotonin transporters and can damage serotonin axon terminals in animals and humans.
  • Serotonin receptor subtypes beyond 5-HT2A (e.g., 5-HT1B) contribute to sustained behavioral effects.

Conflicts

  • Some work attributes psychedelic subjective effects mainly to serotonin/norepinephrine systems, while one study found norepinephrine release, not serotonin or dopamine, tracked amphetamine-type subjective effects.
  • Psilocybin's acute effects are attributed to 5-HT2A, but sustained anxiolytic effects are attributed to 5-HT1B, suggesting different receptors drive different phases.
  • Intracellular 5-HT2A receptors are proposed to mediate plasticity, implying endogenous serotonin may not engage the same mechanisms as psychedelics.

Gaps

  • Human clinical efficacy data are limited to small, mostly open-label studies.
  • Durability of psilocybin's structural and behavioral effects beyond one month is largely untested.
  • Dose-response and dosing-schedule effects (including microdosing) remain inadequately studied.
  • Most mechanistic evidence comes from rodent, in vitro, and computational models rather than humans.
  • Long-term serotonin neuron recovery after MDMA exposure in humans is unclear.
  • Sex- and stress-dependent effects of serotonin receptor modulation are underexplored.
Browse these studies in the library

Common questions

What does the research agree on about serotonin?
  • 5-HT2A receptor activation is consistently linked to psilocybin's acute psychedelic and psychosis-like effects.
  • Serotonin receptors are structurally and pharmacologically diverse, with ligand-binding differences producing distinct signaling outcomes.
  • Psilocybin and related serotonergic drugs can produce lasting neural and behavioral changes beyond acute effects.
  • MDMA-type drugs act on serotonin transporters and can damage serotonin axon terminals in animals and humans.
  • Serotonin receptor subtypes beyond 5-HT2A (e.g., 5-HT1B) contribute to sustained behavioral effects.
Where do studies on serotonin conflict?
  • Some work attributes psychedelic subjective effects mainly to serotonin/norepinephrine systems, while one study found norepinephrine release, not serotonin or dopamine, tracked amphetamine-type subjective effects.
  • Psilocybin's acute effects are attributed to 5-HT2A, but sustained anxiolytic effects are attributed to 5-HT1B, suggesting different receptors drive different phases.
  • Intracellular 5-HT2A receptors are proposed to mediate plasticity, implying endogenous serotonin may not engage the same mechanisms as psychedelics.
What is still unknown about serotonin?
  • Human clinical efficacy data are limited to small, mostly open-label studies.
  • Durability of psilocybin's structural and behavioral effects beyond one month is largely untested.
  • Dose-response and dosing-schedule effects (including microdosing) remain inadequately studied.
  • Most mechanistic evidence comes from rodent, in vitro, and computational models rather than humans.
  • Long-term serotonin neuron recovery after MDMA exposure in humans is unclear.
  • Sex- and stress-dependent effects of serotonin receptor modulation are underexplored.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Serotonin, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Serotonin or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

3,994 articles · 1,021 from the last two years · 636,316 participants across 795 studies reporting sample size

Common study designs

review 826 experimental study 610 observational cohort 145 randomized controlled trial 132 theoretical or philosophical paper 174

Research volume by year

Compare topics →

1,317 studies whose primary subject is serotonin since 2002

Studies about serotonin per year, 2002 to 2026, peaking at 162 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 100 200 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about serotonin per year, 2002 to 2026, peaking at 162 in 2026
Year Studies
2002 16
2003 16
2004 21
2005 26
2006 30
2007 28
2008 34
2009 25
2010 31
2011 44
2012 26
2013 32
2014 41
2015 23
2016 46
2017 44
2018 73
2019 45
2020 62
2021 59
2022 86
2023 91
2024 105
2025 151
2026 162

Research

Synthesize the evidence → Search all →

Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice.

Psychopharmacology October 17, 2026 Sixtine Fleury, Yian Shang, Katherine M. Nautiyal

Psilocybin can produce rapid and sustained antidepressant-like and anxiolytic effects, yet the receptor and circuit mechanisms underlying these behavioral changes remain unclear. While the serotonin 2A receptor mediates psilocybin's acute psychedelic effects, psilocin (the active metabolite of psilocybin) binds many serotonin receptor subtypes. Our prior work has identified the serotonin 1B...

DOI: 10.1007/s00213-026-07184-8 (opens in new tab) Full text (opens in new tab) Anxiety Psilocybin 5-ht1br Desynchrony +2

Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways

CNS & Neurological Disorders - Drug Targets October 14, 2026 Sheekha Chaudhary, Sanchit Dhankhar, Monika Saini et al.

More than fifty million individuals worldwide are experiencing neurodegenerative disorders, which include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and frontotemporal dementia. These disorders have a significant role in the gradual degradation of cognition and motor skills. Most current treatment approaches have little...

DOI: 10.2174/0118715273491538261009064612 (opens in new tab)

Serotonin 2A receptors in the medial prefrontal cortex do not drive DOI-induced head-twitch responses in rodents

bioRxiv (Cold Spring Harbor Laboratory) October 11, 2026 Ratna Mahathi Vuruputuri, Vaishnavi Reghunath, Shreyasi Mukherjee et al. preprint

Abstract Background The head-twitch response (HTR) is a serotonin 2A receptor (5-HT 2A R) dependent behavioral correlate of serotonergic psychedelic action in rodent models. Although cortical 5-HT 2A Rs have been implicated in HTRs, the contribution of specific cortical circuits to this behavior remains poorly defined, with a few reports implicating the medial prefrontal cortex (mPFC) in the...

DOI: 10.64898/2026.10.05.756681 (opens in new tab) Full text (opens in new tab)

Serotonin biology as a basis for explaining psychedelic drug action.

Current Biology October 5, 2026 Cory A. Knox, Athena Li-Wu, Alex C. Kwan

Psychedelics exert their effects primarily through the serotonergic system. Like the endogenous neuromodulator, the drugs bind to many serotonin receptor subtypes. However, their receptor selectivity profiles and spatiotemporal patterns of action differ from those of serotonin and vary across compounds. In this review, we summarize studies that have established roles for serotonin in three...

DOI: 10.1016/j.cub.2026.08.045 (opens in new tab) Full text (opens in new tab)

Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics.

Psychopharmacology September 29, 2026 Praneet Suresh, Josie Kins, Lex Levkovskyy et al.

Psychedelics exhibit rapid, durable therapeutic effects across diverse psychiatric conditions, yet their broad-spectrum psychoactivity poses challenges for clinical translation. As a proof-of-concept, we aimed to quantify associations between 19 neurotransmitter receptors and the subjective effects of 21 psychedelic drugs with broadly assayed binding profiles. We used a custom Global Vectors...

DOI: 10.1007/s00213-026-07170-0 (opens in new tab) Full text (opens in new tab) Hypothesis generation Natural language processing Psychedelics Receptor binding profiles +1

Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics.

Brain, Behavior, and Immunity September 28, 2026 Anna Skovgaard Lerche, Dennis Parker Kelley, Michael E Benros et al.

Serotonergic psychedelics are promising treatments for neuropsychiatric disorders, and their immunomodulatory effects may contribute to their clinical efficacy. However, we lack a systematic review and meta-analysis of these effects across in vitro, in vivo non-human, and human studies. We systematically searched PubMed, EMBASE, Web of Science, PsycINFO, LILACS and ClinicalTrials.gov for all...

DOI: 10.1016/j.bbi.2026.107033 (opens in new tab) Full text (opens in new tab) 5-ht2ar Inflammation Meta-analysis Serotonergic psychedelics +1

Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure

Zenodo (CERN European Organization for Nuclear Research) September 27, 2026 Andrea Vittorini preprint

This hypothesis and perspective article proposes that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research. Existing controlled studies relevant to depression and mood have predominantly used intermittent schedules. The first dedicated randomized trial in major depressive disorder used 2 mg psilocybin once weekly and did not demonstrate...

DOI: 10.5281/zenodo.23001108 (opens in new tab)

Deciphering the allosteric landscape of 5-HT2 receptors: integrated molecular dynamics and fragment molecular orbital analyses of activation mechanisms

Pharmacological Reports September 25, 2026 Paweł Śliwa, Karina Pakosz, Aleksandra Banach

Abstract Background The 5-HT 2 receptor subfamily (5-HT 2A , 5-HT 2B , and 5-HT 2C ) is a cornerstone of neuropsychiatric drug design, yet the precise molecular determinants of their activation and biased signaling remain only partially elucidated. This study aimed to investigate the conformational transitions and energetic landscapes across diverse functional states to provide a refined...

DOI: 10.1007/s43440-026-00909-8 (opens in new tab) Full text (opens in new tab)

Exploring a Druggable Hydrophobic Tunnel in the 5-HT2A Receptor with Potent Phenethylamines

Journal of Medicinal Chemistry September 25, 2026 Icaro A Simon, Eline Pottie, Madeleine K. Jensen et al.

The serotonin 2A receptor is the most abundant excitatory serotonin receptor in the brain and the target for serotonergic psychedelics. Despite its importance, the mechanisms of action and structure−activity relationship of receptor agonists are not fully understood. Experimental 5-HT2AR structures have identified a hydrophobic tunnel lateral to the orthosteric site. Here, we have examined this...

DOI: 10.1021/acs.jmedchem.6c01973 (opens in new tab)

The serotonin 1B receptor as a target for the treatment of depression and anxiety

Expert Opinion on Therapeutic Targets September 21, 2026 Sixtine Fleury, Katherine M. Nautiyal

INTRODUCTION: Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related pathology. AREAS COVERED: We synthesize converging evidence from human and...

DOI: 10.1080/14728222.2026.2738183 (opens in new tab)

Clinical trials

All Serotonin trials →